SAB Biotherapeutics(US:SABS) Globenewswireยท2025-05-09 13:00Core Viewpoint - SAB BIO is making significant progress in developing its immunotherapy platform aimed at delaying the onset or progression of type 1 diabetes (T1D), with recent positive Phase 1 topline data for its lead asset, SAB-142 [2][5]. Recent Pipeline Developments - In April 2025, SAB BIO completed patient dosing in the last cohort of the Phase 1 clinical study of SAB-142, indicating advancement in its clinical trials [2]. Corporate Updates from Q1 2025 - The company has implemented budget initiatives that are contributing to cost savings, particularly in manufacturing processes, which are expected to enhance financial performance in 2025 [7]. - SAB BIO has achieved a Qualified Person (QP) declaration for its in-house CMC manufacturing process for SAB-142, meeting European manufacturing standards for investigational medical drug products [7]. Q1 2025 Financial Results - As of March 31, 2025, SAB BIO held cash and equivalents of $12.9 million, down from $20.8 million as of December 31, 2024 [7]. - Research and development (R&D) expenses were $7.7 million for Q1 2025, a slight decrease from $8.1 million in Q1 2024, attributed to fluctuations in spending priorities for the SAB-142 program [7]. - General and administrative expenses decreased to $3.1 million in Q1 2025 from $4.2 million in Q1 2024, driven by reduced payroll and professional fees [7]. - Other income for Q1 2025 was $5.6 million, down from $6.4 million in Q1 2024, primarily due to changes in fair value of warrant liabilities and reduced net interest income [7]. - The company reported a net loss of $5.2 million for Q1 2025, compared to a net loss of $5.0 million for Q1 2024 [7].